Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jul 2;14(7):13748–13762. doi: 10.3390/ijms140713748

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by the authors; licensee MDPI, Basel, Switzerland

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

PMC Copyright notice

Relationship between KRAS/MAPK1 amplification or p-ERK expression status and progression-free/overall survival in patients who received primary cytoreductive surgery followed by standard platinum/taxane chemotherapy. (A,B) Kaplan-Meier survival analysis showed that KRAS amplification (solid line, n = 9) was not associated with a shorter progression-free/overall survival than absence of KRAS amplification (dashed line, n = 59; p = 0.5897, p = 0.8655, respectively, Log-rank test); (C) Kaplan-Meier survival analysis showed that MAPK1 amplification (solid line, n = 5) was associated with a shorter progression-free survival than absence of MAPK1 amplification (dashed line, n = 63; p = 0.0098, Log-rank test); (D) MAPK1 amplification (solid line, n = 5) tended to be correlated with a shorter overall survival than absence of MAPK1 amplification, but was not statistically significant (dashed line, n = 63; p = 0.1658, Log-rank test); (E,F) Positive p-ERK expression tended to be correlated with a shorter progression-free/overall survival than absence of MAPK1 amplification, but was not statistically significant (dashed line, n = 63; p = 0.2396, p = 0.0943, respectively, Log-rank test).

Relationship between KRAS/MAPK1 amplification or p-ERK expression status and progression-free/overall survival in patients who received primary cytoreductive surgery followed by standard platinum/taxane chemotherapy. (A,B) Kaplan-Meier survival analysis showed that KRAS amplification (solid line, n = 9) was not associated with a shorter progression-free/overall survival than absence of KRAS amplification (dashed line, n = 59; p = 0.5897, p = 0.8655, respectively, Log-rank test); (C) Kaplan-Meier survival analysis showed that MAPK1 amplification (solid line, n = 5) was associated with a shorter progression-free survival than absence of MAPK1 amplification (dashed line, n = 63; p = 0.0098, Log-rank test); (D) MAPK1 amplification (solid line, n = 5) tended to be correlated with a shorter overall survival than absence of MAPK1 amplification, but was not statistically significant (dashed line, n = 63; p = 0.1658, Log-rank test); (E,F) Positive p-ERK expression tended to be correlated with a shorter progression-free/overall survival than absence of MAPK1 amplification, but was not statistically significant (dashed line, n = 63; p = 0.2396, p = 0.0943, respectively, Log-rank test).